HRP20221448T1 - Il-22 fc pripravci i postupci njihove primjene - Google Patents
Il-22 fc pripravci i postupci njihove primjene Download PDFInfo
- Publication number
- HRP20221448T1 HRP20221448T1 HRP20221448TT HRP20221448T HRP20221448T1 HR P20221448 T1 HRP20221448 T1 HR P20221448T1 HR P20221448T T HRP20221448T T HR P20221448TT HR P20221448 T HRP20221448 T HR P20221448T HR P20221448 T1 HRP20221448 T1 HR P20221448T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- fusion protein
- preparation according
- amino acid
- seq
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 24
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000002919 epithelial cell Anatomy 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 210000000936 intestine Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 235000011008 sodium phosphates Nutrition 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 238000005251 capillar electrophoresis Methods 0.000 claims 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 210000002175 goblet cell Anatomy 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 claims 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 1
- 235000019799 monosodium phosphate Nutrition 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Dental Preparations (AREA)
Claims (14)
1. Farmaceutski pripravak, naznačen time, da sadrži fuzijski protein IL-22 Fc i nosač, gdje je fuzijski protein IL-22 Fc koji sadrži polipeptid IL-22 povezan s Fc regijom pomoću veznice, pri čemu farmaceutski pripravak sadrži
oko 1 mg/ml do oko 10 mg/ml fuzijskog proteina IL-22 Fc,
oko 5 mM metionina,
oko 10 mM natrijeva fosfata i oko 240 mM saharoze,
i oko 0,02 % (m/v) polisorbata 20, pH 7,1, u konačnoj koncentraciji.
2. Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time, da je natrijev fosfat smjesa monobaznog natrijeva fosfata i dvobaznog natrijeva fosfata.
3. Farmaceutski pripravak prema patentnim zahtjevima 1 ili 2, naznačen time, da farmaceutski pripravak sadrži oko 10 mg/ml fuzijskog proteina IL-22 Fc.
4. Farmaceutski pripravak prema patentnim zahtjevima 1 ili 2, naznačen time, da farmaceutski pripravak sadrži oko 1 mg/ml fuzijskog proteina IL-22 Fc.
5. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da:
(i) farmaceutski pripravak je u obliku jedinične doze;
(ii) nosač je voda;
(iii) farmaceutski pripravak je stabilan tijekom jednog ili više ciklusa zamrzavanja-odmrzavanja;
(iv) farmaceutski pripravak je stabilan oko 2 tjedna ili duže na temperaturi od oko 25 °C;
(v) farmaceutski pripravak je stabilan oko 48 mjeseci ili dulje na temperaturi od -20 °C;
(vi) farmaceutski pripravak posjeduje čistoću od oko 85 % ili više, kako je procijenjeno tekućinskom kromatografijom visoke djelotvornosti s isključenjem na osnovu veličine čestica (SE-HPLC);
(vii) farmaceutski pripravak posjeduje čistoću od oko 75 % ili više, kako je procijenjeno nereduciranom (NR) kapilarnom elektroforezom u natrijevom dodecil-sulfatu bez gela (CE-SDS-NGS);
(viii) farmaceutski pripravak se formulira za intravenoznu, supkutanu, intraperitonealnu ili topikalnu primjenu;
(ix) farmaceutski pripravak ne sadrži konzervans; i/ili
(x) farmaceutski pripravak se formulira za primjenu putem infuzije nakon razrjeđivanja izotoničnom otopinom natrijeva klorida i/ili razrjeđivačem.
6. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da:
(i) polipeptid IL-22 je glikoziliran;
(ii) Fc regija nije glikozilirana;
(iii) aminokiselinski ostatak na položaju 297 je Gly ili Ala kao u EU indeksu Fc regije i/ili aminokiselinski ostatak na položaju 299 je Ala, Gly ili Val kao u EU indeksu Fc regije;
(iv) Fc regija sadrži CH2 i CH3 domenu IgG1 ili IgG4; i/ili
(v) fuzijski protein IL-22 Fc sadrži aminokiselinski slijed koji ima najmanje 95 % identičnosti slijeda s aminokiselinskim slijedom SEQ ID NO: 8.
7. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da fuzijski protein IL-22 Fc sadrži ili se sastoji od aminokiselinskog slijeda SEQ ID NO: 8, SEQ ID NO: 10 ili SEQ ID NO: 16.
8. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da fuzijski protein IL-22 Fc sadrži aminokiselinski slijed SEQ ID NO: 8.
9. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da nadalje sadrži dodatno terapeutsko sredstvo i/ili sredstvo za želiranje.
10. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da se farmaceutski pripravak primjenjuje intravenozno, supkutano, intraperitonealno ili topikalno.
11. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da je za uporabu kao lijek.
12. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da je za uporabu u
(i) liječenju upalne bolesti crijeva (IBD),
(ii) inhibiranju mikrobne infekcije u crijevima, očuvanju vrčastih stanica u crijevu tijekom mikrobne infekcije, poboljšanju integriteta epitelnih stanica, proliferaciji epitelnih stanica, diferencijaciji epitelnih stanica, migraciji epitelnih stanica ili zacjeljivanju epitelnih rana u crijevima,
(iii) liječenju akutne ozljede bubrega ili akutnog pankreatitisa,
(iv) ubrzavanju ili poboljšanju zacjeljivanja rana, ili
(v) sprečavanju ili liječenju kardiovaskularnog stanja.
13. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 12, naznačen time, da je IBD ulcerozni kolitis ili Crohnova bolest.
14. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 13, naznačen time, da je ulcerozni kolitis umjeren do teški ulcerozni kolitis.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622704P | 2018-01-26 | 2018-01-26 | |
| US201862697372P | 2018-07-12 | 2018-07-12 | |
| PCT/US2019/015268 WO2019148020A1 (en) | 2018-01-26 | 2019-01-25 | Compositions and methods of use |
| EP19704966.1A EP3743088B1 (en) | 2018-01-26 | 2019-01-25 | Il-22 fc compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221448T1 true HRP20221448T1 (hr) | 2023-01-20 |
Family
ID=65409540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221448TT HRP20221448T1 (hr) | 2018-01-26 | 2019-01-25 | Il-22 fc pripravci i postupci njihove primjene |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20200353049A1 (hr) |
| EP (1) | EP3743088B1 (hr) |
| JP (1) | JP7345479B2 (hr) |
| KR (1) | KR20200125590A (hr) |
| CN (1) | CN112020365A (hr) |
| AU (1) | AU2019212703A1 (hr) |
| BR (1) | BR112020015016A2 (hr) |
| CA (1) | CA3088763A1 (hr) |
| DK (1) | DK3743088T3 (hr) |
| ES (1) | ES2932861T3 (hr) |
| HR (1) | HRP20221448T1 (hr) |
| HU (1) | HUE060435T2 (hr) |
| IL (1) | IL276135A (hr) |
| LT (1) | LT3743088T (hr) |
| MX (1) | MX2020007628A (hr) |
| PL (1) | PL3743088T3 (hr) |
| PT (1) | PT3743088T (hr) |
| RS (1) | RS63812B1 (hr) |
| SI (1) | SI3743088T1 (hr) |
| WO (1) | WO2019148020A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| WO2017181143A1 (en) | 2016-04-15 | 2017-10-19 | Generon (Shanghai) Corporation, Ltd. | Use of il-22 in treating necrotizing enterocolitis |
| TW202118793A (zh) * | 2019-07-26 | 2021-05-16 | 美商建南德克公司 | 以 IL-22 Fc 融合蛋白預防或治療移植物抗宿主疾病 (GVHD) 之投藥 |
| WO2021164744A1 (en) * | 2020-02-19 | 2021-08-26 | Evive Biotechnology (Shanghai) Ltd | Methods for treating graft versus host disease |
| WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
| CA3211978A1 (en) * | 2021-03-09 | 2022-09-15 | Gi Innovation, Inc. | Formulation of fusion protein including extracellular domain of alpha subunit of ige fc receptor |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4717717A (en) | 1986-11-05 | 1988-01-05 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| US5705485A (en) | 1987-09-18 | 1998-01-06 | Ethicon, Inc. | Gel formulations containing growth factors |
| US5457093A (en) | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
| NZ226171A (en) | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| KR0154872B1 (ko) | 1987-12-21 | 1998-10-15 | 로버트 에이. 아미테이지 | 발아하는 식물종자의 아크로박테리움 매개된 형질전환 |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5130298A (en) | 1989-05-16 | 1992-07-14 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| AU758178B2 (en) | 1998-09-04 | 2003-03-20 | Scios Inc. | Hydrogel compositions for the controlled release administration of growth factors |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
| ATE303445T1 (de) | 1999-10-04 | 2005-09-15 | Medicago Inc | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| AU2002339845B2 (en) | 2001-08-03 | 2009-03-26 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
| US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
| WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| SI1572744T1 (sl) | 2002-12-16 | 2010-09-30 | Genentech Inc | Imunoglobulinske variante in njihove uporabe |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
| TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| DK1737891T3 (da) | 2004-04-13 | 2013-03-25 | Hoffmann La Roche | Anti-p-selectin-antistoffer |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| BRPI0613284A2 (pt) | 2005-06-17 | 2010-12-28 | Genentech Inc | métodos de aceleração de cicatrização de ferida |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| WO2011087986A1 (en) * | 2010-01-13 | 2011-07-21 | Amgen Inc. | Il-22-fc and hepcidin activity |
| ES2617777T5 (es) | 2010-04-23 | 2022-10-13 | Hoffmann La Roche | Producción de proteínas heteromultiméricas |
| AR084210A1 (es) * | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
| AR094821A1 (es) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| AR095496A1 (es) * | 2013-03-15 | 2015-10-21 | Bayer Healthcare Llc | Formulaciones de anticuerpos anti-receptor de prolactina |
| JP6456356B2 (ja) | 2013-03-15 | 2019-01-23 | ジェネンテック， インコーポレイテッド | ＩＬ−２２ポリペプチド及びＩＬ−２２Ｆｃ融合タンパク質並びに使用方法 |
| EP3624846A1 (en) * | 2017-05-16 | 2020-03-25 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
-
2019
- 2019-01-25 EP EP19704966.1A patent/EP3743088B1/en active Active
- 2019-01-25 HU HUE19704966A patent/HUE060435T2/hu unknown
- 2019-01-25 MX MX2020007628A patent/MX2020007628A/es unknown
- 2019-01-25 BR BR112020015016-9A patent/BR112020015016A2/pt unknown
- 2019-01-25 PT PT197049661T patent/PT3743088T/pt unknown
- 2019-01-25 SI SI201930399T patent/SI3743088T1/sl unknown
- 2019-01-25 CA CA3088763A patent/CA3088763A1/en active Pending
- 2019-01-25 PL PL19704966.1T patent/PL3743088T3/pl unknown
- 2019-01-25 DK DK19704966.1T patent/DK3743088T3/da active
- 2019-01-25 WO PCT/US2019/015268 patent/WO2019148020A1/en unknown
- 2019-01-25 LT LTEPPCT/US2019/015268T patent/LT3743088T/lt unknown
- 2019-01-25 AU AU2019212703A patent/AU2019212703A1/en active Pending
- 2019-01-25 KR KR1020207021787A patent/KR20200125590A/ko not_active Application Discontinuation
- 2019-01-25 RS RS20221131A patent/RS63812B1/sr unknown
- 2019-01-25 CN CN201980022499.7A patent/CN112020365A/zh active Pending
- 2019-01-25 JP JP2020540787A patent/JP7345479B2/ja active Active
- 2019-01-25 ES ES19704966T patent/ES2932861T3/es active Active
- 2019-01-25 HR HRP20221448TT patent/HRP20221448T1/hr unknown
-
2020
- 2020-07-19 IL IL276135A patent/IL276135A/en unknown
- 2020-07-24 US US16/938,777 patent/US20200353049A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3743088T (pt) | 2022-12-05 |
| TW201938794A (zh) | 2019-10-01 |
| PL3743088T3 (pl) | 2023-03-20 |
| AU2019212703A1 (en) | 2020-08-13 |
| BR112020015016A2 (pt) | 2020-12-29 |
| KR20200125590A (ko) | 2020-11-04 |
| WO2019148020A1 (en) | 2019-08-01 |
| JP2021511362A (ja) | 2021-05-06 |
| SI3743088T1 (sl) | 2023-01-31 |
| CA3088763A1 (en) | 2019-08-01 |
| MX2020007628A (es) | 2020-10-12 |
| LT3743088T (lt) | 2022-12-27 |
| DK3743088T3 (da) | 2022-12-19 |
| EP3743088A1 (en) | 2020-12-02 |
| IL276135A (en) | 2020-09-30 |
| HUE060435T2 (hu) | 2023-03-28 |
| RS63812B1 (sr) | 2023-01-31 |
| ES2932861T3 (es) | 2023-01-27 |
| JP7345479B2 (ja) | 2023-09-15 |
| EP3743088B1 (en) | 2022-10-12 |
| US20200353049A1 (en) | 2020-11-12 |
| CN112020365A (zh) | 2020-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221448T1 (hr) | Il-22 fc pripravci i postupci njihove primjene | |
| JP6199298B2 (ja) | メグルミンによって安定化されたエタネルセプト製剤 | |
| JP2023145766A (ja) | 抗体含有製剤 | |
| US20230301901A1 (en) | Use of il-22 dimer in manufacture of a medicament for intravenous administration | |
| KR20120135387A (ko) | 에타너셉트의 안정한 용액 제형 | |
| WO2009014263A1 (ja) | インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤 | |
| US11141479B2 (en) | Stable anti-OSMR antibody formulation | |
| KR102385802B1 (ko) | Gm-csf 중화 화합물을 포함하는 액체 제제 | |
| RU2020128111A (ru) | ВЕДЕНИЕ БЕЛКОВ СЛИЯНИЯ IL-22 Fc ДЛЯ ЛЕЧЕНИЯ | |
| JP6825181B2 (ja) | 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用 | |
| RU2020129180A (ru) | Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы | |
| WO2016162867A1 (en) | Combination therapy of macrophage activating factor and pd-1 signaling inhibitors | |
| CA3200525A1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| BR112019013673A2 (pt) | composição farmacêutica aquosa de anticorpo anti-tnfa monoclonal recombinante | |
| CN110536698A (zh) | 重组单克隆抗TNFα抗体的水性药用组合物 | |
| Woo et al. | GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv (UCHT1) for phase I/II clinical trials | |
| WO2022242527A1 (zh) | 一种单克隆抗体-细胞因子融合蛋白制剂 | |
| JPWO2019148020A5 (hr) | ||
| CA3196989A1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| WO2022129311A1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| JPWO2019165140A5 (hr) | ||
| JPH07503705A (ja) | 医薬的リジン含有ポリペプチド組成物およびその使用法 | |
| CN115531298A (zh) | 稳定的抗TNFα单克隆抗体的液体制剂 | |
| US20240052026A1 (en) | Stable antibody formulation, preparation method therefor, and applications thereof | |
| RU2017146821A (ru) | Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОа |